Vera Therapeutics, Inc. Other Comprehensive Income (Loss), Tax
Vera Therapeutics, Inc. (VERA) reported Other Comprehensive Income (Loss), Tax of $29.85 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement
us-gaap:OtherComprehensiveIncomeLossTax · last filed 2023-05-11
- Vera Therapeutics, Inc. other comprehensive income (loss), tax for the quarter ending 2023-03-31 was $29.85M, a 74.59% increase year-over-year.
- Vera Therapeutics, Inc. other comprehensive income (loss), tax for the quarter ending 2022-12-31 was $146.18M, a 202.20% increase year-over-year.
- Vera Therapeutics, Inc. other comprehensive income (loss), tax for the quarter ending 2022-09-30 was -$24.81M.
- Vera Therapeutics, Inc. other comprehensive income (loss), tax for the quarter ending 2022-06-30 was -$14.99M.
- Vera Therapeutics, Inc. other comprehensive income (loss), tax for fiscal 2022 was $89.28M, a 173.79% increase from fiscal 2021.
- Vera Therapeutics, Inc. other comprehensive income (loss), tax for fiscal 2021 was $32.61M.
| Period end | Other Comprehensive Income (Loss), Tax 3 month | Other Comprehensive Income (Loss), Tax 3 month as first filed | Other Comprehensive Income (Loss), Tax 6 month | Other Comprehensive Income (Loss), Tax 9 month | Other Comprehensive Income (Loss), Tax 12 month |
|---|---|---|---|---|---|
| 2023-03-31 | $29.85M 10-Q · filed 2023-05-11 | $176.03M derived: sum of 2 quarters · filed 2023-05-11 | $151.22M derived: sum of 3 quarters · filed 2023-05-11 | $136.23M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-12-31 | $146.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $121.37M derived: sum of 2 quarters · filed 2023-03-28 | $106.38M derived: sum of 3 quarters · filed 2023-03-28 | $89.28M 10-K · filed 2023-03-28 | |
| 2022-09-30 | -$24.81M 10-Q · filed 2022-11-09 | -$39.80M derived: sum of 2 quarters · filed 2022-11-09 | -$56.90M 10-Q · filed 2022-11-09 | $25.67M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-06-30 | -$14.99M 10-Q · filed 2022-08-10 | -$32.09M 10-Q · filed 2022-08-10 | $50.48M derived: sum of 3 quarters · filed 2023-05-11 | $42.86M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-03-31 | $17.10M 10-Q · filed 2023-05-11 | -$17.10M 10-Q · filed 2022-05-16 | $65.47M derived: sum of 2 quarters · filed 2023-05-11 | $57.86M derived: sum of 3 quarters · filed 2023-05-11 | $54.42M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $48.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $40.76M derived: sum of 2 quarters · filed 2023-03-28 | $37.32M derived: sum of 3 quarters · filed 2023-03-28 | $32.61M 10-K · filed 2023-03-28 | |
| 2021-09-30 | -$7.61M 10-Q · filed 2022-11-09 | -$11.05M derived: sum of 2 quarters · filed 2022-11-09 | -$15.76M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | -$3.44M 10-Q · filed 2022-08-10 | -$8.15M 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | $4.71M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |